Systemic Pharmacotherapeutic Treatment of the ACTA1-MCM/ FLExDUX4 Preclinical Mouse Model of FSHD

Keyphrases

• Preclinical Animal Models 100%
• Pharmaceutics 100%
• Double Homeobox 100%
• ACTA1 100%
• Facioscapulohumeral muscular Dystrophy 100%
• Berberine 50%
• Skeletal muscle 25%
• Muscle Strength 12%
• Muscle Mass 12%
• Protein Level 12%
• Therapeutic Potential 12%
• Mouse Model 12%
• MRNA Expression 12%
• MRNA Level 12%
• Patient-derived 12%
• Vector-based 12%
• Overexpressing 12%
• Aberrant Expression 12%
• Transgenic Mouse Model 12%
• Myoblast 12%
• Viral Vectors 12%
• Muscle Pathology 12%
• Intraperitoneal Injection 12%
• Forelimb muscle 12%
• Cellular Pathways 12%
• Inhibitory Efficacy 12%
• Dosing Regimen 12%
• Herbal Extracts 12%

Neuroscience

• Muscular Dystrophy 100%
• Homeobox 100%
• Berberine 50%
• Skeletal Muscle 25%
• Messenger RNA 25%
• Virus Vector 12%
• Histopathology 12%
• Intraperitoneal Injection 12%
• Myoblast 12%
• Tamoxifen 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse Model 100%
• Facioscapulohumeral Muscular Dystrophy 100%
• Berberine 57%
• Messenger RNA 28%
• Tamoxifen 14%
• Bioavailability 14%
• Transgenic Mouse 14%
• Viral Vector 14%
• Intraperitoneal Injection 14%